SmithKline and Glaxo's merger to cost £112m in fees

When pharmaceutical giants SmithKline Beecham and Glaxo Wellcome officially complete their merger on August 21 the two companies will have committed to spend nearly £112m (€179.2m) on advisory fees.

The fees, which neither company will break down for the public, will, according to a spokesperson at SmithKline Beecham, go to 12 different firms.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump